Raymond James Maintains Strong Buy On Incyte As Firm Sees Many Catalysts In 2019 Including the 'potential approval of rux in SR acute GVHD', 'Phase III results from the REACH2 and REACH3 studies in SR-aGVHD and SR chronic GVHD', Among Others
Benzinga_Newsdesk